Biomatrix systems theory

BioMatrix Specialty Pharmacy Recognized by the National Association for Business Resources with a 2023 Best and Brightest Company to Work For Award

Retrieved on: 
Thursday, September 21, 2023

PLANTATION, Fla., Sept. 21, 2023 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today the organization has been recognized with a fifth consecutive "Best and Brightest Companies to Work For in the Nation" award. The National Association for Business Resources (NABR) first awarded BioMatrix with the national distinction in 2019, then again in 2020, 2021, 2022, and 2023. The BioMatrix corporate headquarters in South Florida has also been selected four times over as a top-performing employer for the Miami area, receiving recognition every year since the NABR instituted regional distinctions beginning in 2020.

Key Points: 
  • PLANTATION, Fla., Sept. 21, 2023 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today the organization has been recognized with a fifth consecutive "Best and Brightest Companies to Work For in the Nation" award.
  • The National Association for Business Resources (NABR) first awarded BioMatrix with the national distinction in 2019, then again in 2020, 2021, 2022, and 2023.
  • BioMatrix Specialty Pharmacy receives fifth consecutive "Best and Brightest Companies to Work For in the Nation" award.
  • "We are so honored to receive our fifth consecutive Best and Brightest award," said Diane Schumacher, VP Human Resources.

SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics

Retrieved on: 
Thursday, July 13, 2023

West Conshohocken, PA, July 13, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard® (uridine triacetate) and Xuriden® (uridine triacetate), from Wellstat Therapeutics.

Key Points: 
  • West Conshohocken, PA, July 13, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard® (uridine triacetate) and Xuriden® (uridine triacetate), from Wellstat Therapeutics.
  • [iii]
    Jeremie Urbain, President of SERB Pharmaceuticals, said: “We’re proud to add these two treatments to our expanding portfolio of medicines for complex, life-threatening conditions.
  • BTG Pharmaceuticals, a SERB company, will promote Vistogard® and continue promoting Voraxaze® through its oncology field force in the US.
  • Today’s news follows the announcement in May that SERB has acquired the exclusive US rights to bentracimab, which is in development as a ticagrelor reversal agent.

BioMatrix Specialty Pharmacy Welcomes Kathee Kramm to Executive Team

Retrieved on: 
Tuesday, May 16, 2023

PLANTATION, Fla., May 16, 2023 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today Kathee Kramm has joined the executive leadership team as President and Chief Operating Officer. Working in collaboration with the CEO and CFO, Kathee will oversee sales, operations, nursing and revenue cycle management. She will play an integral role in BioMatrix's strategic priorities as a leader in the specialty infusion pharmacy industry.

Key Points: 
  • PLANTATION, Fla., May 16, 2023 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today Kathee Kramm has joined the executive leadership team as President and Chief Operating Officer.
  • She will play an integral role in BioMatrix's strategic priorities as a leader in the specialty infusion pharmacy industry.
  • Ms. Kramm is an accomplished, entrepreneurial healthcare executive extensively experienced in specialty pharmacy and home infusion.
  • "We are excited to partner with Kathee and welcome her to our executive leadership team," CEO Nick Karalis affirms.

BIOCARE NAMES TWO HEALTHCARE INDUSTRY VETERANS TO LEADERSHIP POSITIONS

Retrieved on: 
Tuesday, February 7, 2023

TEMPE, Ariz., Feb. 7, 2023 /PRNewswire/ -- BioCare, Inc., specializing in delivering specialty and therapeutic biological products since 1982, has named two healthcare industry veterans to their leadership team. Healthcare sales executive Mike Collins was named Vice President of Sales for BioCareSD, the company's specialty distribution business. Operations executive Kevin Kissling was named Vice President & General Manager 3PL Services, leading LogiCare3PL, BioCare's third-party logistics offering.

Key Points: 
  • Healthcare Sales Executive Mike Collins to Lead Sales Team; Senior Operations Executive Kevin Kissling to Head LogiCare3PL
    TEMPE, Ariz., Feb. 7, 2023 /PRNewswire/ -- BioCare, Inc., specializing in delivering specialty and therapeutic biological products since 1982, has named two healthcare industry veterans to their leadership team.
  • Healthcare sales executive Mike Collins was named Vice President of Sales for BioCareSD, the company's specialty distribution business.
  • "We are thrilled to bring two industry veterans with deep experience in their specialties to the BioCare team," said CEO Linda Matthews.
  • Throughout his 25-year career in the healthcare industry, Collins has experience working with pharmaceutical, biopharmaceutical, and specialty pharmacy organizations.

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

Retrieved on: 
Monday, January 30, 2023

NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Patrick Fabbio as Chief Financial Officer effective January 30, 2023.

Key Points: 
  • NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Patrick Fabbio as Chief Financial Officer effective January 30, 2023.
  • Mr. Fabbio most recently served as President and Chief Financial Officer at NYSE-listed Rafael Holdings, Inc.
    “We are excited to welcome Pat to the Protara leadership team,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
  • “With his impressive track record as a financial executive, Pat brings more than 30 years of experience in life science and pharmaceutical companies to Protara.
  • “I am eager to contribute to the important work Protara is doing and support the Company’s growth as well as its commitment to advance its pipeline of transformative therapies.”
    Prior to joining Protara, Mr. Fabbio served as President and Chief Financial Officer at Rafael Holdings, Inc.

Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company

Retrieved on: 
Tuesday, January 17, 2023

ROSEVILLE, Minn. and SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-generation plant breeding.

Key Points: 
  • The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-generation plant breeding.
  • Renewable Low-Carbon Ingredients: Gene editing is a key tool in the development of sustainable low-carbon ingredients that can replace fossil fuel-based ingredients and diesel fuel.
  • In addition, Cibus and Calyxt are both working with leading consumer product companies to develop more sustainable ingredients.
  • Under the terms of the merger agreement, Calyxt will issue shares of its common stock to Cibus shareholders in an exchange ratio such that upon completion of the merger, Calyxt shareholders will own approximately 5% of the combined company, subject to adjustments permitted by the merger agreement.

BioMatrix Specialty Pharmacy Recognized by the National Association for Business Resources with a 2022 Best and Brightest Company to Work For Award

Retrieved on: 
Tuesday, December 13, 2022

PLANTATION, Fla., Dec. 13, 2022 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today the organization has been recognized with a fourth consecutive "Best and Brightest Companies to Work For in the Nation" award. The National Association for Business Resources (NABR) first awarded BioMatrix with the national distinction in 2019, then again in 2020, 2021, and 2022. The BioMatrix corporate headquarters in South Florida has also been selected three times over as a top-performing employer for the Miami area, receiving recognition every year since the NABR instituted regional distinctions beginning in 2020.  

Key Points: 
  • PLANTATION, Fla., Dec. 13, 2022 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today the organization has been recognized with a fourth consecutive "Best and Brightest Companies to Work For in the Nation" award.
  • The National Association for Business Resources (NABR) first awarded BioMatrix with the national distinction in 2019, then again in 2020, 2021, and 2022.
  • BioMatrix Recognized with Fourth Consecutive 2022 Best & Brightest Company to Work For Award in 2022
    BioMatrix competed against 3,500 companies for the "Best and Brightest" distinction.
  • Best and Brightest companies are assessed by an independent research firm on a number of key measures and industry benchmarks.

BIOMATRIX PROUDLY ANNOUNCES THE 2022 MEMORIAL SCHOLARSHIP RECIPIENTS

Retrieved on: 
Tuesday, November 29, 2022

PLANTATION, Fla., Nov. 29, 2022 /PRNewswire/ -- Each year, BioMatrix provides six $1,000 scholarships for bleeding disorders community members seeking higher education. Since 2013, our scholarships have honored the memory of several individuals who impacted the bleeding disorders community in unique ways. BioMatrix partners with the Hemophilia Federation of America for administrative support and independent, third-party evaluation of applicants.

Key Points: 
  • PLANTATION, Fla., Nov. 29, 2022 /PRNewswire/ -- Each year, BioMatrix provides six $1,000 scholarships for bleeding disorders community members seeking higher education.
  • BioMatrix partners with the Hemophilia Federation of America for administrative support and independent, third-party evaluation of applicants.
  • It is with great pleasure we announce the 2022 recipients of our Memorial Scholarship Program.
  • Without further ado, we introduce you to our scholarship recipients!

BioMatrix Specialty Pharmacy Granted Preferred Status with AscellaHealth for Home Infusion Therapies

Retrieved on: 
Tuesday, February 8, 2022

PLANTATION, Fla., Feb. 8, 2022 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today inclusion as a preferred provider in AscellaHealth's home infusion pharmacy network.

Key Points: 
  • PLANTATION, Fla., Feb. 8, 2022 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today inclusion as a preferred provider in AscellaHealth's home infusion pharmacy network.
  • BioMatrix Specialty Pharmacy provides robust specialty infusion services, including site of care coordination.
  • Using a nationwide network of highly trained specialty infusion nurses, BioMatrix coordinates over 1,200 home nursing visits every month.
  • BioMatrix Specialty Pharmacy, an Inc. 5000 company, offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions.

AscellaHealth Offers Home Infusion Pharmacy Network, Complements Site of Care Optimization and Overall Strategy to Cut Costs While Ensuring Care Quality

Retrieved on: 
Tuesday, February 8, 2022

Recognizing the importance of SOC optimization, AscellaHealth offers a Home Infusion Pharmacy Network as part of our overall strategy to cut costs without compromising quality of care , says Dea Belazi, president and CEO, AscellaHealth.

Key Points: 
  • Recognizing the importance of SOC optimization, AscellaHealth offers a Home Infusion Pharmacy Network as part of our overall strategy to cut costs without compromising quality of care , says Dea Belazi, president and CEO, AscellaHealth.
  • Our pharmacy providers were chosen for their national reach, high-touch capabilities and thorough home infusion expertise, enabling care delivery in the highest-quality, lowest-cost care settings and enhancing outcomes via increased compliance rates.
  • These select providers, including Amber Specialty Pharmacy , AcariaHealth and BioMatrix Specialty Pharmacy , can improve drug affordability for patients and providers, increase price transparency and reduce disparities in quality of care and safety.
  • Specialty drugs are used to treat complex, chronic or rare conditions and require special administration or handling with infusion therapies.